---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-013552"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:12:41.817937+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Esperion to acquire Corstasis for $75M upfront; adds Enbumyst nasal spray for heart failure edema

## Summary
- Esperion acquires Corstasis for $75M cash upfront; up to $180M in milestones plus low double-digit royalties on Enbumyst sales.
- Enbumyst (bumetanide nasal spray) is first FDA-approved nasal spray diuretic for edema in CHF, hepatic, renal disease (approved Sep 2025).
- Esperion expects to leverage its cardiovascular commercial infrastructure to drive double-digit revenue growth; addresses $4B+ U.S. market.
- Transaction financed via existing credit facilities and royalty monetization; expected close Q2 2026.
- Corstasis also developing subcutaneous multidose pen injector; complements Esperion's pipeline in metabolic, hepatic, renal disease.

## SEC filing metadata
- accession: 0001628280-26-013552
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/0001628280-26-013552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/espr-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-013552
- JSON: https://secwatch.observer/filing/0001628280-26-013552.json
- Plain text: https://secwatch.observer/filing/0001628280-26-013552.txt

## Key facts
- Material Agreements
  Esperion Therapeutics, Inc. entered into Agreement and Plan of Merger with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”) valued at $75,000,000 (effective 2026-03-02).
  - Action: entry
  - Agreement: merger
  - Counterparty: Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”)
  - Value: $75,000,000
  - Effective: 2026-03-02
  source text: On March 2, 2026, Esperion Therapeutics, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/0001628280-26-013552-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.